MTOR and tuberous sclerosis: The relevance of hyperactive mTORC1 signaling in TSC, or mTORopathies in general, is further underscored by the clinical use of mTOR inhibitors for inoperable SEGA lesions and as an add-on treatment of DRE in TSC (Curatolo et al., 2018; Muhlebner et al., 2019; Moavero et al., 2021).